NCT03462342 2026-03-17
CAPRI
University of Pennsylvania
Phase 2 Completed
Clinical Trials
53 trialsNCT05340413 2026-03-16
RADIOLA
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT02787642 2026-02-25
RADIOSARP
Institut Bergonié
Phase 1 Completed
NCT03025035 2026-02-06
Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
Cedars-Sinai Medical Center
Phase 2 Completed
NCT03685331 2026-01-09
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT01858168 2025-12-19
Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma
Massachusetts General Hospital
Phase 1 Completed
NCT03109080 2025-11-24
RadioPARP
Institut Curie
Phase 1 Completed
NCT03259503 2025-11-10
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02755844 2025-10-02
ENDOLA
Hospices Civils de Lyon
Phase 1/2 Completed
NCT03516812 2025-09-29
Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer
University of Washington
Phase 2 Completed
NCT03561870 2025-09-12
OLAGLI
Hospices Civils de Lyon
Phase 2 Completed
NCT04076579 2025-08-29
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT05320757 2025-06-11
Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients
The University of Hong Kong
Phase EARLY_PHASE1 Completed
NCT04306367 2025-02-17
Study of Pembrolizumab and Olaparib in Bile Duct Cancer
Georgetown University
Phase 2 Completed
NCT03532880 2025-02-07
A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03314740 2025-01-10
BAROCCO
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT03745950 2024-12-04
UTOLA
ARCAGY/ GINECO GROUP
Phase 2 Completed
NCT02953457 2024-11-19
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Roswell Park Cancer Institute
Phase 2 Completed
NCT03378297 2024-10-30
IMPACT
Haukeland University Hospital
Phase EARLY_PHASE1 Completed
NCT03205761 2024-10-18
COMETABreast
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT02677038 2024-10-01
Olaparib in Treating Patients With Stage IV Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02338622 2024-09-26
ComPAKT
Royal Marsden NHS Foundation Trust
Phase 1 Completed
NCT01513174 2024-06-28
GOAL
Spanish Lung Cancer Group
Phase 1/2 Completed
NCT03127215 2024-05-08
NCT-PMO-1603
National Center for Tumor Diseases, Heidelberg
Phase 2 Completed
NCT03117933 2024-01-23
OCTOVA
University of Oxford
Phase 2 Completed
NCT02117167 2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2 Completed
NCT03448718 2023-11-22
Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
Hoosier Cancer Research Network
Phase 2 Completed
NCT04152941 2023-09-06
RETROLA
ARCAGY/ GINECO GROUP
Completed
NCT04166435 2023-09-06
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer
Yale University
Phase 2 Completed
NCT04417192 2023-07-06
OLAPem
National Cancer Center Hospital East
Phase 2 Completed
NCT04774406 2023-06-06
Arterial Hypertension Related to PARP Inhibitors (ArteRIB)
University Hospital, Caen
Completed
NCT03434158 2022-11-03
IMANOL
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT03470805 2022-09-23
Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma
Grupo Español de Investigación en Cáncer de Ovario
Phase 2 Completed
NCT02477644 2022-08-02
PAOLA-1
Arcagy Research
Phase 3 Completed
NCT02681237 2022-05-09
A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer
University Health Network, Toronto
Phase NA Completed
NCT02855697 2022-02-22
MOLTO
The Christie NHS Foundation Trust
Phase EARLY_PHASE1 Completed
NCT04774627 2021-09-23
Pancytopenia Related to PARP Inhibitors (PancytoRIB)
University Hospital, Caen
Completed
NCT03057145 2021-09-02
Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02227082 2021-08-04
Olaparib and Radiotherapy in Inoperable Breast Cancer
The Netherlands Cancer Institute
Phase 1 Completed
NCT03009682 2021-02-18
SUKSES-B
Samsung Medical Center
Phase 2 Completed
NCT03428607 2021-02-18
Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]
Samsung Medical Center
Phase 2 Completed
NCT01623349 2021-02-10
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02506816 2020-11-30
Polen
MedSIR
Completed
NCT03544125 2020-11-20
Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer
OHSU Knight Cancer Institute
Phase 1 Completed
NCT02121990 2020-08-21
Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03534492 2020-04-06
NEODURVARIB
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT02882308 2020-02-07
OPHELIA
Hellenic Cooperative Oncology Group
Phase 2 Completed
NCT01758731 2019-09-23
Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History
University of Colorado, Denver
Phase 1 Completed
NCT02324998 2019-08-29
CaNCaP03
Cambridge University Hospitals NHS Foundation Trust
Phase 1 Completed
NCT02418624 2019-01-16
REVIVAL
The Netherlands Cancer Institute
Phase 1 Completed